PLX3397 Pexidartinib C Kit Inhibitors
Chemical Information
|
Product name:PLX3397 Pexidartinib |
Purity:98% min |
|
CAS NO:1029044-16-3 |
Solubility:DMSO : 5 mg/mL (11.97 mM); H2O : < 0.1 mg/mL |
|
Molecular Formula:C20H15ClF3N5 |
Package:Package according to customer requirements |
|
Molecular Weight:417.815 |
Storage:Store at -20℃ |
Remarks
Pexidartinib (PLX-3397) is a potent, selective and ATP-competitive CSF1R (cFMS) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases, such as FLT3, KDR (VEGFR2), LCK, FLT1 (VEGFR1) and NTRK3 (TRKC), with IC50s of 160, 350, 860, 880, and 890 nM, respectively.
Related Products:
Pexidartinib hcl; Telatinib; Avapritinib; Amuvatinib; Dovitinib Lactate; Linifanib; OSI-930; Crenolanib; Motesanib Diphosphate; Motesanib; Sunitinib; Imatinib mesylate; Axitinib; Masitinib; Dovitinib; ISCK03
References
[1]. DeNardo DG, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011 Jun;1(1):54-67.
[2]. Kuse Y, et al. Microglia increases the proliferation of retinal precursor cells during postnatal development. Mol Vis. 2018 Jul 30;24:536-545. eCollection 2018.
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.